BRIEF published on 09/29/2025 at 23:05, 5 months 16 days ago GenSight Biologics Announces First Half 2025 Financial Results Financial Results Research And Development Treasury GenSight Biologics Early Access Programs
PRESS RELEASE published on 09/29/2025 at 23:00, 5 months 16 days ago Inside Information / News release on accounts, results GenSight Biologics reports 8.3% reduction in operating cash outflow and extends cash runway to late Q4 2025. Company's financial results show decrease in operating income, R&D expenses, and net cash flows Financial Results Operating Income Cash Management GenSight Biologics R&D Expenses
PRESS RELEASE published on 09/29/2025 at 21:48, 5 months 16 days ago rapport financier semestriel 2025
BRIEF published on 08/28/2025 at 20:05, 6 months 18 days ago GenSight Biologics Delays 2025 Half-Year Financial Results Announcement Financial Results Regulatory Compliance Postponement GenSight Biologics Audit Procedures
PRESS RELEASE published on 08/28/2025 at 20:00, 6 months 18 days ago Inside Information / Other news releases GenSight Biologics postpones the release of its 2025 half-year financial results to September 29, 2025, after the market closes, to ensure highest audit standards. No material issues reported. Audit Committee and Board meetings rescheduled Financial Results Transparency Postponement GenSight Biologics Audit Procedures
BRIEF published on 07/17/2025 at 15:05, 7 months 29 days ago GenSight Biologics: Publication of an article on the predictions of LUMEVOQ® gene therapy Gene Therapy GenSight Biologics NOHL LUMEVOQ Visual Acuity
PRESS RELEASE published on 07/17/2025 at 15:00, 7 months 29 days ago Inside Information / Other news releases GenSight Biologics announces publication on predictors of final visual outcome in patients treated with LUMEVOQ® gene therapy. Study identifies key factors for improved visual acuity post-treatment Gene Therapy GenSight Biologics LUMEVOQ Visual Outcome Predictive Factors
BRIEF published on 07/17/2025 at 08:05, 7 months 30 days ago GenSight Biologics raises 500,000 euros to strengthen its development Funding GenSight Biologics Phase III Gene Therapies LUMEVOQ
BRIEF published on 07/03/2025 at 21:24, 8 months 12 days ago GenSight Biologics completes private placement of nearly €4 million Private Placement Common Shares Euronext Funding GenSight Biologics
PRESS RELEASE published on 07/03/2025 at 21:19, 8 months 12 days ago Inside Information / Operations of the issuer (acquisitions, sales...) GenSight Biologics closes EUR 3.9M private placement with issuance of ordinary shares, pre-funded warrants, investor warrants. Funds to repay convertible bonds. Maxim Group, LLC acted as placement agent Private Placement Ordinary Shares GenSight Biologics Maxim Group EUR 3.9M
Published on 03/16/2026 at 11:30, 28 minutes ago Relevant Gold Announces $15 Million Strategic Financing with Participation from Kinross, Bollinger, and McEwen
Published on 03/16/2026 at 11:00, 58 minutes ago Vox Royalty Announces Inclusion in MVIS(R) Global Junior Gold Miners Index and VanEck Junior Gold Miners ETF (GDXJ)
Published on 03/16/2026 at 11:00, 58 minutes ago Banyan Intercepts Several New Distinct High-grade Silver Veins, including 3,408 g/t Ag over 1.4 m, at AurMac, Yukon
Published on 03/15/2026 at 23:25, 12 hours 33 minutes ago Tunkillia 'Phase 2' Resource Upgrade Drilling Begins
Published on 03/16/2026 at 11:30, 28 minutes ago Tourism Authority of Thailand premieres 'Healing Journey Thailand' global campaign in London, advancing healing led tourism vision.
Published on 03/16/2026 at 11:00, 58 minutes ago BIO-Europe Spring® 2026: Partnering Momentum Builds as Global Biopharma Leaders Set Course for Lisbon
Published on 03/16/2026 at 11:00, 58 minutes ago CTS EVENTIM: EVENTIM LIVE expands in the French live market with promoter Pierre-Alexandre Vertadier
Published on 03/16/2026 at 11:00, 58 minutes ago Vossloh to deliver high-speed grinding train to China
Published on 03/16/2026 at 11:00, 58 minutes ago Nebius signs new AI infrastructure agreement with Meta
Published on 03/16/2026 at 08:30, 3 hours 28 minutes ago CDA - Update on CDA' parks solarization program
Published on 03/13/2026 at 19:50, 2 days 16 hours ago Availability of ENGIE’S 2025 Universal Registration Document
Published on 03/13/2026 at 18:05, 2 days 17 hours ago Availability of the 2025 Universal Registration Document of OPmobility SE
Published on 03/13/2026 at 07:30, 3 days 4 hours ago BIOPHYTIS PRESENTS ITS DEVELOPMENT PROGRAMS IN OBESITY AND SARCOPENIA AT THE ICFSR CONFERENCE
Published on 03/12/2026 at 18:00, 3 days 17 hours ago NEW OR RENEWED AGREEMENTS BETWEEN EURAZEO AND CERTAIN FAMILY SHAREHOLDERS
